NURIX THERAPEUTICS IN

Nurix Therapeutics to Participate in Upcoming Investor Conferences

09 Mar 2022 15:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting

08 Mar 2022 15:47:52 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference

10 Feb 2022 15:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update

27 Jan 2022 15:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts

10 Jan 2022 06:00:03 By Nasdaq GlobeNewswire

Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 15:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

12 Dec 2021 08:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors

12 Nov 2021 06:09:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference

12 Nov 2021 06:07:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

09 Nov 2021 15:01:01 By Nasdaq GlobeNewswire

Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit

26 Oct 2021 15:02:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit

21 Oct 2021 06:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

14 Oct 2021 15:02:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders

30 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

13 Jul 2021 15:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development

21 Jun 2021 15:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease

02 Jun 2021 06:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors

01 Jun 2021 15:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress

21 May 2021 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

11 May 2021 06:00:01 By Nasdaq GlobeNewswire